Roche Immunotherapy Tecentriq Gains European Approval for Breast Cancer Roche Immunotherapy Tecentriq Gains European Approval for Breast Cancer
Roche ' s Tecentriq (atezolizumab) has won European approval for use against a tough-to-treat breast cancer, helping the Swiss drugmaker to widen use of an immunotherapy that has so far been eclipsed in revenue terms by more-established rival medicines.Reuters Health Information
Source: Medscape Allergy Headlines - Category: Allergy & Immunology Tags: Hematology-Oncology News Source Type: news
More News: Allergy | Allergy & Immunology | Breast Cancer | Cancer | Cancer & Oncology | Hematology | Immunotherapy | Switzerland Health